Nevertheless, the prognostic power of CCNA2 in ER+ breast cancer and its relation with tamoxifen resistance have never been reported before.[16] In this study, we explored the possibility of CCNA2 as a biomarker for the prognosis of ER+ breast cancer patients and prediction of tamoxifen efficacy. The gene discussed is ESR1; the disease is breast cancer.